IP Library › Granted Patent US 9,844,584
Granted Patent B2
US 9,844,584 · App. 14/400,293 · Granted Dec 19, 2017

Composition for preventing or treating sepsis

Inventor: Sang Jae Kim (Seoul, KR)
Assignee: GEMVAX & KAEL CO., LTD.
A61K38/45A23L33/18A61K9/0019A61K38/10C12N9/1276A23V2002/00A61K38/00C12Y207/07049
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,844,584
App. No.
14/400,293
Granted
Dec 19, 2017
Kind
B2
Abstract

Provided in the present invention is a peptide for preventing or treating sepsis. The peptide can improve symptoms of sepsis by inhibiting production of TNF, IL-1, and IL-6, which are cytokines that are related to sepsis, or can prevent or treat sepsis. Also disclosed are a pharmaceutical composition or a food composition containing the peptide as an active ingredient, a usage of the peptide for preventing or treating sepsis, and a kit comprising the peptide and instructions.

Claims (12)

1. A method for preventing or treating sepsis comprising administering to a subject in need thereof the isolated peptide of SEQ ID NO: 1.

2. The method according to claim 1 , wherein the peptide is administered in a single dose at a concentration of 0.1 μg/kg to 1.0 g/kg.

3. The method according to claim 1 , wherein the peptide is administered in a single dose at a concentration of 1 μg/kg to 10 mg/kg.

4. The method according to claim 1 , wherein the peptide is administered 1 to 3 times a day.

5. The method according to claim 4 , wherein the peptide is administered at a daily dose of 0.1 μm/kg to 1.0 g/kg.

6. A method for preventing or treating sepsis comprising administering to a subject in need thereof a composition comprising the isolated peptide of SEQ ID NO: 1.

7. The method of claim 6 , wherein the composition is administered through oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, intramedullary, epidural, or subcutaneous routes.

8. The method of claim 6 , wherein the composition comprises 0,1 μg/ing to 1 mg/mg of isolated peptide.

9. The method of claim 6 , wherein the peptide is administered in a single dose at a concentration of 0.1 μg/kg to 1.0 g/kg.

10. The method of claim 6 , wherein the peptide is administered in a single dose at a concentration of 1 μg/kg to 10 mg/kg.

11. The method of claim 6 , wherein the peptide is administered 1 to 3 times a day.

12. The method of claim 11 , wherein the peptide is administered at a daily dose of 0.1 μg/kg to 1.0 g/kg.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2015
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 036678/0469 →
Priority Claims (4)
KR 10-2012-0050529 · May 11, 2012 · national
KR 10-2012-0050533 · May 11, 2012 · national
KR 10-2012-0071989 · Jul 2, 2012 · national
KR 10-2012-0104207 · Sep 19, 2012 · national
Continuity (1)
Related Publication 20160008438A1 · Jan 14, 2016